Recent years have seen considerable rise in the cases of non-alcoholic and alcohol-
associated/related liver disease. Though largely, a reversible condition in early stages, if left …

Non-alcoholic fatty liver disease (NAFLD) is a multifaceted metabolic disorder, whose
spectrum covers clinical, histological and pathophysiological developments ranging from …

Nonalcoholic steatohepatitis (NASH) is emerging as the primary driver of liver disease-
induced fibrosis. The imperative need for noninvasive biomarkers to ascertain disease …

This review intends to uncover how information from large-scale genetic profiling (whole
genome sequencing, and whole exome sequencing) of nonalcoholic fatty liver disease …

Nonalcoholic steatohepatitis (NASH) is a major cause of liver fibrosis with increasing
prevalence worldwide. Currently there are no approved drugs available. The development …

Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD) and its severe clinical
form, metabolic dysfunctionassociated steatohepatitis (MASH), are chronic liver diseases …

Non-alcoholic fatty liver disease (NAFLD) is a widespread contributor to chronic liver
disease globally. A recent consensus on renaming liver disease was established, and …

Nonalcoholic fatty liver disease (NAFLD) is a common cause of hepatic abnormalities
worldwide. Nonalcoholic steatohepatitis (NASH) is part of the spectrum of NAFLD and leads …

The new nomenclature of metabolic dysfunction-associated steatotic liver disease (MASLD)
emphasizes a positive diagnosis based on cardiometabolic risk factors. This definition is not …

Non-alcoholic fatty liver disease (NAFLD) is the most common liver pathology characterized
by fat accumulation in a context of metabolic syndrome or insulin resistance. It can be …